Literature DB >> 33911102

Seasonal prevalence and characteristics of low-dose CT detected lung nodules in a general Dutch population.

Harriet L Lancaster1, Marjolein A Heuvelmans2, Gert Jan Pelgrim1, Mieneke Rook1,3, Marius G J Kok1, Ahmed Aown1, Geertruida H de Bock2, Maarten van den Berge4, Harry J M Groen4, Rozemarijn Vliegenthart5.   

Abstract

We investigated whether presence and characteristics of lung nodules in the general population using low-dose computed tomography (LDCT) varied by season. Imaging in Lifelines (ImaLife) study participants who underwent chest LDCT-scanning between October 2018 and October 2019 were included in this sub-study. Hay fever season (summer) was defined as 1st April to 30th September and Influenza season (winter) as 1st October to 31st March. All lung nodules with volume of ≥ 30 mm3 (approximately 3 mm in diameter) were registered. In total, 2496 lung nodules were found in 1312 (38%) of the 3456 included participants (nodules per participant ranging from 1 to 21, median 1). In summer, 711 (54%) participants had 1 or more lung nodule(s) compared to 601 (46%) participants in winter (p = 0.002). Of the spherical, perifissural and left-upper-lobe nodules, relatively more were detected in winter, whereas of the polygonal-, irregular-shaped and centrally-calcified nodules, relatively more were detected in summer. Various seasonal diseases with inflammation as underlying pathophysiology may influence presence and characteristics of lung nodules. Further investigation into underlying pathophysiology using short-term LDCT follow-up could help optimize the management strategy for CT-detected lung nodules in clinical practice.

Entities:  

Year:  2021        PMID: 33911102     DOI: 10.1038/s41598-021-88328-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  3 in total

1.  The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups.

Authors:  Michael T Jaklitsch; Francine L Jacobson; John H M Austin; John K Field; James R Jett; Shaf Keshavjee; Heber MacMahon; James L Mulshine; Reginald F Munden; Ravi Salgia; Gary M Strauss; Scott J Swanson; William D Travis; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2012-07       Impact factor: 5.209

2.  Lung-Cancer Screening and the NELSON Trial. Reply.

Authors:  Harry J de Koning; Carlijn M van der Aalst; Matthijs Oudkerk
Journal:  N Engl J Med       Date:  2020-05-28       Impact factor: 91.245

3.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.